Skip to main content

Table 2 Proportion of patients with reduction in tumor size >0%, >10% and >30%, for patients with vs without selected resistance/sensitivity biomarkers

From: Fool’s gold, lost treasures, and the randomized clinical trial

Drug Tumor type Biomarker % Biomarker-positive patients with tumor shrinkagea % Biomarker-negative patients with tumor shrinkagea
Tumor shrank > 0% Tumor shrank > 10% Tumor shrank > 30% Tumor shrank > 0% Tumor shrank > 10% Tumor shrank > 30%
Panitumumab [52] Colorectal KRAS wild type 57% 50% 25% 4% 1% 0%
Erlotinib [84] NSCLC EGFR mutant 100% 83% 72% 28% 12% 8%
Erlotinib [85] NSCLC EGFR mutant 100% 83% 50% 31% 17% 3%
Erlotinib [86] NSCLC EGFR mutant 90% 88% 76%    
Erlotinib [87] NSCLC EGFR mutant 100% 80% 70%    
Gefitinib [88] NSCLC EGFR mutant 95% 95% 63% 72% 38% 10%
Gefitinib [89] NSCLC EGFR mutant 91% 82% 55% 67% 33% 0%
Erlotinib or gefitinib [63] NSCLC EGFR mutant 97% 91% 84% 45% 22% 9%
Crizotinib [90] NSCLC EML4/ALK fusion 94% 88% 69%    
Vemurafenib [8] Melanoma BRAF V600E 96% 93% 76%    
  1. a. Calculated from manual measurement of available waterfall plots.